Hormonal Intrauterine Devices (IUDs) Market Report 2024

This Hormonal Intrauterine Devices (IUDs) market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The hormonal intrauterine devices (IUDs) market size has grown rapidly in recent years. It will grow from $2.36 billion in 2023 to $2.61 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth observed during the historic period can be attributed to several factors, including the development of safer and more effective hormonal formulations, a rising demand for long-term birth control solutions, increased recommendations from healthcare providers, greater public awareness of contraceptive options, and advancements in medical technology and device design.

The hormonal intrauterine devices (IUDs) market size is expected to see rapid growth in the next few years. It will grow to $3.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth during the forecast period can be attributed to several factors, including rising awareness of contraceptive choices, an increasing preference for long-acting reversible contraception, advancements in device safety and efficacy, a growing emphasis on personalized healthcare, and broader availability through healthcare providers. Key trends expected during this period include advancements in device technology, increasing personalization of contraceptive options, growth in patient-centric healthcare approaches, rising demand for sustainable and eco-friendly products, and the development of new contraceptive products.

The rising incidence of unwanted pregnancies is projected to drive the growth of the hormonal intrauterine devices market in the future. Unwanted pregnancies refer to those that are not planned or desired at the time of conception and can arise from various factors, such as contraceptive failure, lack of access to birth control, improper use of contraception, or sexual violence. Limited access to effective contraceptive methods diminishes individuals' control over their reproductive choices, increasing the likelihood of unwanted pregnancies. Hormonal IUDs are highly effective in preventing pregnancy, boasting a failure rate of less than 1%. They offer long-term protection (ranging from 3 to 7 years, depending on the specific type) and serve as a reliable option for those looking to avoid unintended pregnancies. For example, in August 2023, the Office for Health Improvement & Disparities, a UK governmental unit within the Department of Health and Social Care, reported that between January and June 2022, there were 123,219 abortions among residents of England and Wales, representing a 17% increase compared to the same period in 2021. Thus, the rise in unwanted pregnancies is contributing to the growth of the hormonal intrauterine devices market.

Key players in the hormonal intrauterine devices market are focusing on developing advanced products, such as levonorgestrel-releasing intrauterine systems, to offer more personalized contraceptive solutions for women. Levonorgestrel-releasing intrauterine systems (LNG-IUS) are hormonal IUDs that steadily release levonorgestrel, a synthetic progestin, into the uterus. This hormone thickens cervical mucus and modifies the uterine lining, preventing sperm from reaching the egg. For instance, in November 2022, Medicines360, a US-based pharmaceutical organization dedicated to improving women’s access to essential medicines and health products, launched the FDA-approved LILETTA. LILETTA is one of the longest-lasting hormonal IUDs available in the U.S., approved for contraception for up to 8 years and for treating heavy menstrual bleeding for up to 5 years. It is approximately 99% effective in preventing pregnancy among diverse populations. The device comes with an ergonomic inserter for easy placement during a consultation and can be removed at any time by a healthcare provider. It is available by prescription, and LILETTA is offered at a reduced price through the 340B drug pricing program, aligning with Medicines360’s mission to enhance access to women’s healthcare.

In January 2024, Medicines360 formed a partnership with DKT WomanCare Global, a France-based company focused on the availability, accessibility, and affordability of sexual and reproductive health products for women. This strategic collaboration aims to enhance the availability and accessibility of the affordable hormonal IUD, Avibela, by raising awareness and expanding market reach, particularly in underserved areas, and is intended to improve global sexual and reproductive health.

Major companies operating in the hormonal intrauterine devices (IUDs) market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Organon & Companies, Gedeon Richter Plc, Meril Life Science Pvt Ltd., Bharat Serums and Vaccines Limited, Teva UK Limited, EurimPharm Produktions GmbH, HRA Pharma SAS, Medicines360, Hll Lifecare Limited, Pregna International Ltd., Allergan plc, Actavis Inc., DKT WomanCare Global, CrossBay Medical Inc., SMB Corporation of India, Oy Leiras, OCON Healthcare.

North America was the largest region in the hormonal intrauterine devices (IUDs) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormonal intrauterine devices (IUDs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hormonal intrauterine devices (IUDs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hormonal intrauterine devices (IUDs) are small, T-shaped plastic devices that are inserted into the uterus and release progestin, a synthetic hormone. These devices prevent pregnancy by thickening cervical mucus to block sperm, thinning the uterine lining to impede implantation, and sometimes suppressing ovulation. Additionally, they can reduce menstrual bleeding and cramping, and in some cases, may stop periods altogether.

The primary types of hormonal IUDs include 13-milligram, 19-milligram, and 52-milligram hormonal IUDs. The 13-milligram hormonal IUDs, which release a low dose of hormones for up to three years, are becoming increasingly popular among women seeking long-acting contraceptive options with lower hormone exposure. The design of these devices varies, including framed and frameless IUDs, and they feature different hormone types such as levonorgestrel-releasing and progesterone-releasing IUDs. These options cater to various age groups, including those aged 20-24, 25-34, and 35-44, among other applications.

The hormonal intrauterine devices (IUDs) market research report is one of a series of new reports that provides hormonal intrauterine devices (IUDs) market statistics, including hormonal intrauterine devices (IUDs) industry global market size, regional shares, competitors with a hormonal intrauterine devices (IUDs) market share, detailed hormonal intrauterine devices (IUDs) market segments, market trends, and opportunities, and any further data you may need to thrive in the hormonal intrauterine devices (IUDs) industry. This hormonal intrauterine device (IUDs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hormonal intrauterine devices (IUDs) market consists of sales of hormone reservoir, strings, and insertion or removal instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.